ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1787

Regulatory Role of JAK-1/TYK2 Signaling on the Pannus Formation: Novel Mechanisms for JAK Inhibitors in Psoriatic Disease

Siba Raychaudhuri1, Christine Abria2 and Smriti K Raychaudhuri2, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2VA Sacramento Medical Center, Mather, CA

Meeting: ACR Convergence 2023

Keywords: Cell-signalling molecules, Fibroblasts, Synovial, Psoriatic arthritis, Synovitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1776–1795) Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In psoriatic arthritis (PsA) aberrant activation/migration of specific T cell subpopulations (Th17/Th9/MAIT cells) in the joint synovium induce synovial inflammation and pannus formation. Several T cell cytokines such as IL-9, IL-17A/IL-17F, IL-22 and IL-23 play critical roles in the pathogenesis of PsA. IL-23 does not have any biological effect on synovial cells (FLS) and IL-17 does not activate the JAK/STAT signaling system. IL-9 and IL-22 have regulatory roles on proliferation of FLS; and as well JAK-1 and 3 are activated by IL-9; and JAK1/TYK2 by IL-22. Here to determine the functional significance of these signaling proteins on pannus formation we hypothesized that IL-9/IL22 induced JAK/STAT signaling regulates the proliferative cascades of FLS in PsA. We studied the regulatory role IL-9 induced JAK-1,3 and IL-22 induced JAK1/TYK2 on FLS biology.

Methods: FLS from PsA (n=10) were cultured as per our standardized protocol (Cytokine.2012;60:38-42) with rIL-9 (10ng/ml) and rIL-22 (100ng/ml). Proliferation was measured by MTT assay and CFSE dilution assay. IL-6, IL-8 and MMP3 levels were determined by ELISA. Immunoblot studies were done to assess JAK1/pJAK1, TYK2/pTYK2, STAT1/pSTAT1, STAT3/pSTAT3. Further to determine the molecular mechanisms of JAK inhibitors (JAKi) these experiments were done in the presence or absence of specific JAKi (JAK-inhibitor, Upadacitinib).

Results: In cultured FLS we observed that rIL-22 and rIL-9 induced increased phosphorylation of JAK1/TYK2 and JAK1/JAK3 respectively compared to the culture media only, (p< 0.01). rIL9/rIL22 also phosphorylated STAT3/RORγt. We observed that the critical events in PsA such as (i) proliferation of FLS (ii) IL-6, IL-8 and MMP-3 production by FLS are induced by rIL-22 and rIL-9 and those were regulated by JAK1/TYK2 and JAK-1,3 respectively. Further pan-JAK inhibitors and other specific JAK-1 and TYK2 inhibitors blocked these effects significantly (p< 0.01). Details of some these observations on the regulatory role of JAK-1 are shown in the Figure 1. Figure-1 demonstrates that rIL-9r/rIL-22 induced proliferation of FLS could be inhibited by blocking JAK-1 with JAKi (upadacitinib) by MTT assay; Figure-2 shows the regulatory role of rIL-22 on JAK/STAT phosphorylation in FLS and Figure-3 demonstrates regulatory role of JAK-1 on FLS in respect to local cytokine and metalloproteinase production.

Conclusion: JAK/STAT signaling system of T cells and its regulatory role in the pathogenesis of psoriatic disease is well established.This study provides a novel insight about the role for JAK-1 and TYK2 signaling on pannus formation and demonstrates novel therapeutic targets for treatment of psoriatic disease.

Supporting image 1

Figure 1: JAK_1 regulates rIL-9/rIL_22 induced proliferation of FLS.

MTT assay results show that rIL-9/rIL_22 induced proliferation of FLS is inhibited by a specific JAK_1 inhibitor (upadacitinib). IL-9 and IL_22 increases FLS proliferation significantly compared to culture media (p<.001, t-test). Upadacitinib at several concentrations show significant inhibition of IL-9/IL_22 induced FLS proliferation compared to IL-9/IL_22 induced proliferation (p<.001).

Supporting image 2

Figure_2:
(A) immunoblot study of FLS demonstrates that rIL_22 induced phosphorylation of JAK_1 and STAT_3 were inhibited by specific JAK_1 inhibitor, upadacitinib.
(B) immunoblot study of FLS demonstrates that rIL-9 induced phosphorylation of JAK_1 and STAT_3 were inhibited by specific JAK_1 inhibitor, upadacitinib.

Supporting image 3

Figure 3:
(A) rIL-9 induced IL-6, IL-8, MMP3 secretion by FLS was inhibited by JAK_1 inhibitor, upadacitinib. FLS were cultured with rIL-9 and several doses of upadacitinib. ELISA assay of culture supernatants showed significant inhibition of IL-6, IL-8 and MMP3 levels.
(B) rIL_22 induced IL-6, IL-8, MMP3 secretion by FLS was inhibited by JAK_1 inhibitor, upadacitinib. FLS were cultured with rIL_22 and several doses of upadacitinib. ELISA assay of culture supernatants showed significant inhibition of IL-6, IL-8 and MMP3 levels.


Disclosures: S. Raychaudhuri: AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Celgene, 2, 5, 6, Eli Lilly, 2, 5, 6, Janssen, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, SUN Pharma, 2, 5, 6, UCB, 2, 5, 6; C. Abria: None; S. Raychaudhuri: None.

To cite this abstract in AMA style:

Raychaudhuri S, Abria C, Raychaudhuri S. Regulatory Role of JAK-1/TYK2 Signaling on the Pannus Formation: Novel Mechanisms for JAK Inhibitors in Psoriatic Disease [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/regulatory-role-of-jak-1-tyk2-signaling-on-the-pannus-formation-novel-mechanisms-for-jak-inhibitors-in-psoriatic-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/regulatory-role-of-jak-1-tyk2-signaling-on-the-pannus-formation-novel-mechanisms-for-jak-inhibitors-in-psoriatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology